Closing Bell Recap: Enlivex Therapeutics Ltd (ENLV) Ends at $0.96, Reflecting a -5.88% Downturn

Abby Carey

In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.

Enlivex Therapeutics Ltd (NASDAQ: ENLV) closed the day trading at $0.96 down -5.88% from the previous closing price of $1.02. In other words, the price has decreased by -$5.88 from its previous closing price. On the day, 0.66 million shares were traded. ENLV stock price reached its highest trading level at $1.06 during the session, while it also had its lowest trading level at $0.95.

Ratios:

For a better understanding of ENLV, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.43 and its Current Ratio is at 6.43. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.02.

Upgrades & Downgrades

In the most recent recommendation for this company, H.C. Wainwright on March 02, 2021, Reiterated its Buy rating but revised its target price to $33 from $22 previously.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ENLV now has a Market Capitalization of 226841120 and an Enterprise Value of 5819119.

Stock Price History:

The Beta on a monthly basis for ENLV is 1.49, which has changed by -0.1570248 over the last 52 weeks, in comparison to a change of 0.13042927 over the same period for the S&P500. Over the past 52 weeks, ENLV has reached a high of $2.10, while it has fallen to a 52-week low of $0.83. The 50-Day Moving Average of the stock is -8.06%, while the 200-Day Moving Average is calculated to be -11.44%.

Shares Statistics:

Over the past 3-months, ENLV traded about 3.67M shares per day on average, while over the past 10 days, ENLV traded about 1818580 shares per day. A total of 24.29M shares are outstanding, with a floating share count of 23.17M. Insiders hold about 4.61% of the company’s shares, while institutions hold 4.41% stake in the company. Shares short for ENLV as of 1764288000 were 1147847 with a Short Ratio of 0.31, compared to 1761868800 on 88743. Therefore, it implies a Short% of Shares Outstanding of 1147847 and a Short% of Float of 0.49.

Earnings Estimates

The stock of Enlivex Therapeutics Ltd (ENLV) is currently being evaluated by 1.0 analysts who are actively contributing to its market rating.The consensus estimate for the next quarter is -$0.13, with high estimates of -$0.13 and low estimates of -$0.13.

Analysts are recommending an EPS of between -$0.58 and -$0.58 for the fiscal current year, implying an average EPS of -$0.58. EPS for the following year is -$0.58, with 2.0 analysts recommending between -$0.57 and -$0.59.

DwinneX
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.